Burgess, Michael R.

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer

Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell

Melanoma and MAPK PathwaysCancer Genomics and Diagnostics

Cited by 183

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Bal, S., Htut, M., Nadeem, O., Anderson, L. D., Koçoğlu, H., Gregory, T., Rossi, A. C., Martin, T., Egan, D. N., Costa, L., et al. (2023) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 59

Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS

An, N., Khan, S., Imgruet, M. K., Gurbuxani, S. K., Konecki, S. N., Burgess, M. R., & McNerney, M. E. (2018) · Blood

Hematopoietic Stem Cell TransplantationAcute Myeloid Leukemia Research

Cited by 55

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Bal, S., Kocoglu, M. H., Nadeem, O., Htut, M., Gregory, T., Anderson, L. D., Costa, L. J., Buchholz, T. J., Ziyad, S., Li, M., et al. (2022) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 38